Meta Glasses for Low Vision

The Use of Meta AI Glasses With Be My Eyes Network to Improve Mobility in Patients With Low Vision

Visual impairment, particularly from glaucoma and retinal dystrophies, significantly hinders mobility and increases the risk of falls, leading to decreased independence and mental health challenges. Current low-vision assistive technologies primarily focus on near-task magnification for reading, leaving a critical gap in tools designed to assist with real-world navigation and peripheral vision loss. To address this, the proposed research evaluates Meta AI glasses, which offer real-time scene narration and object recognition, integrated with the Be My Eyes network. The study hypothesizes that this wearable AI technology will improve ambulation, orientation, and overall quality of life for patients, providing a functional solution for mobility that traditional devices lack.

Study Overview

• Status: Not yet recruiting
• Conditions: Irreversible Vision Loss
• Intervention / Treatment: Other: Meta AI Glasses; Other: Control

Detailed Description

Background

Visual impairment, including both low vision and blindness, ranks among the 10 most prevalent causes of disability in North America1. Glaucoma causes irreversible vision loss, and treatments are only available to prevent disease onset and progression, but no cure is available.2. Patients with vision loss have impairments in both physical and mental health, thus limiting their activities of daily living (ADLs).3 In turn, these patients exhibit a decreased quality of life which can result in lowered self-esteem and depression.4,5 In patients with glaucoma, functional loss often begins with glare sensitivity, mobility and difficulty ambulating.5 Due to decreased peripheral vision, patients tend to have an increased risk of accidents and falls. One study found that glaucoma patients walked up to 10% slower than those without glaucoma4. In turn, these patients experienced almost twice as many bumps, stumbles and orientation issues as compared to non-glaucomatous patients.6

Low visual acuity significantly impairs mobility in patients with retinal dystrophies, as it reduces the ability to detect obstacles, navigate unfamiliar environments, and maintain safe ambulation, especially under variable lighting conditions. Performance-based assessments such as the multi-luminance mobility test (MLMT) demonstrate that reduced visual acuity, along with diminished visual field and contrast sensitivity, correlates with slower travel speed, increased collisions, and greater difficulty in orientation and navigation tasks in real-world settings.7,8

Rationale for the Proposed Research

Although a range of low-vision devices is currently available, none are explicitly designed to address mobility as a primary functional outcome. Existing technologies largely target near tasks through optical magnification, providing support for seated reading but offering limited benefit for individuals whose major challenges stem from peripheral visual field loss or real-world navigation difficulties, an unmet need in patients with glaucoma and many inherited retinal disorders.

In contrast, Meta AI glasses represent a new class of wearable assistive technology with capabilities that extend far beyond magnification. These glasses integrate real-time scene narration, environmental description, object recognition, and access to remote human assistance, offering dynamic support across diverse and mobile settings. Their onboard sensors and AI-driven interface also create the possibility of functional visual field assessment and continuous contextual guidance features fundamentally different from traditional low vision devices.

While these devices, known as Meta AI glasses, are gradually becoming more integrated into clinical care, no formal study has yet evaluated their specific impact on mobility in patients with low vision. Understanding whether AI-enhanced wearable devices can improve ambulation, orientation, and functional independence in low vision patients represents an important next step in advancing both clinical practice and patient outcomes.

This proposal aims to evaluate the performance and impact on the quality of life of Meta AI glasses in patients with low vision.

Hypothesis

Use of Meta AI Glasses integrated with the Be My Eyes network will improve mobility and quality of life in patients with low vision.

Objectives

The principal objective of this study is to evaluate the utility of Meta AI Glasses integrated with the Be My Eyes network on mobility in patients with significantly restricted visual fields or low visual acuity.

Specific Aim:

Mobility: To assess whether use of the device improves ambulation, orientation, and navigation safety in real-world .

1. Project design, methodology and analysis This study will be conducted at the Ivey Eye Institute at St. Joseph's Health Care in London, Ontario. Eligible patients with a documented visual field loss will be identified from ophthalmology practices within the institute.

The following inclusion and exclusion criteria will be implemented:

Inclusion criteria:

1. Confirmed diagnosis of glaucoma, retinal dystrophy, or another condition associated with legal blindness.
2. Presence of documented irreversible vision loss
3. No surgical or laser procedures in the last 6 months
4. Visual field worse than 12db or poor visual acuity 20/400 or worse

Exclusion criteria:

1. Has no access to telephone
2. Unable to speak English
3. Has previously received comprehensive low vision services

5. Has history of stroke with aphasia 6. Has other health condition that would preclude follow-up (e.g., significant malignancy or life-threatening disease) 7. Is unable or unwilling to attend clinic visits required for the study 8. Reports significant loss of vision since last eye exam

Participants will be randomized into two groups:

1. Intervention group: 25 Patients receiving standard care for their eye condition will be provided with customized Meta AI Glasses integrated with the Be My Eyes network. Each patient will receive training on device use, followed by an adaptation period where they incorporate the glasses into their daily activities.
2. Control group: 25 Patients will continue receiving standard care and will not receive the Meta AI glasses during the study period.

The randomization will be conducted in a 1:1 ratio to either the intervention group (Meta AI Glasses + Be My Eyes) or the control group (usual low-vision care). Randomization will be performed using a computer-generated sequence with allocation concealment through a centralized system. Outcome assessors and data analysts will remain masked to group assignment, and analyses will follow the intention-to-treat principle.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Monali Malvankar; Phone Number: 61288 519-685-8500; Email: mmalvan@uwo.ca
• Study Contact Backup: Name: Cindy Hutnik; Phone Number: 66272 519-646-6100; Email: Cindy.Hutnik@sjhc.london.on.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Confirmed diagnosis of glaucoma, retinal dystrophy, or another condition associated with legal blindness.
2. Presence of documented irreversible vision loss
3. No surgical or laser procedures in the last 6 months
4. Visual field worse than 12db or poor visual acuity 20/400 or worse

Exclusion Criteria:

1. Has no access to telephone
2. Unable to speak English
3. Has previously received comprehensive low vision services

5. Has history of stroke with aphasia 6. Has other health condition that would preclude follow-up (e.g., significant malignancy or life-threatening disease) 7. Is unable or unwilling to attend clinic visits required for the study 8. Reports significant loss of vision since last eye exam

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Meta AI Glasses; 25 Patients receiving standard care for their eye condition will be provided with customized Meta AI Glasses integrated with the Be My Eyes network. Each patient will receive training on device use, followed by an adaptation period where they incorporate the glasses into their daily activities.	Other: Meta AI Glasses; Meta AI glasses in patients with low vision
Sham Comparator: Control; Control group: 25 Patients will continue receiving standard care and will not receive the Meta AI glasses during the study period.	Other: Control; 25 Patients will continue receiving standard care and will not receive the Meta AI glasses during the study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
patient-reported vision-targeted quality of life	The primary outcome will be change in patient-reported vision-targeted quality of life, measured using the National Eye Institute Visual Function Questionnaire - 25 item (NEI VFQ-25).	4 weeks

Collaborators and Investigators

• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): July 1, 2027

Study Registration Dates

• First Submitted: December 19, 2025
• First Submitted That Met QC Criteria: December 19, 2025
• First Posted (Actual): January 5, 2026

Study Record Updates

• Last Update Posted (Actual): January 5, 2026
• Last Update Submitted That Met QC Criteria: December 19, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: 128336

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: IP will not be shared because it is not allowed by the Western Research Ethics Board and the Lawson Research Institute REB committee.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No